Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB

References

1. Adorini L., Appella E., Doria G., Nagy Z. A. 1988; Mechanisms influencing the immunodominance of T cell determinants. Journal of Experimental Medicine 168:2091–2099
   [Google Scholar]
2. Bakay M., Beladi I., Berencsi K., Sidorova E., Agadzanyan M., Fachet J., Erdei J. 1992; Immunoenhancement and suppression induced by adenovirus in chickens. Acta virologica 36:269–276
   [Google Scholar]
3. Berencsi K., Gönczöl E., Valyi-Nagy T., Uri A., Rando R., deTaisne C., Plotkin S. A. 1991; Recombinant human cytomegalovirus (HCMV)-gB glycoprotein induces gB-specific cell-mediated immunity in mice. In Proceedings of the 3rd International Cytomegalovirus Workshop, Bologna pp 191–194 Edited by Landini M. P. Netherlands: Elsevier;
   [Google Scholar]
4. Borysiewicz L., Hickling J., Graham S., Sinclair L., Cranage M., Smith G., Sissons J. 1988; Human cytomegalovirus specific cytotoxic T cells–relative frequency of stage specific CTL recognizing the 72 kDa immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. Journal of Experimental Medicine 168:919–931
   [Google Scholar]
5. Britt W. J., Vugler L., Stephens E. B. 1988; Induction of complement dependent and independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp 55-116 (gB). Journal of Virology 62:3309–3318
   [Google Scholar]
6. Brit W. J., Vugler L., Butfiloski E. J., Stephens E. B. 1990; Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. Journal of Virology 64:1079–1085
   [Google Scholar]
7. Browne H., Smith G., Beck S., Minson T. 1990; A complex between the MHC class I homologue encoded by human cytomegalovirus and β 2 microglobulin. Nature, London 347:770–772
   [Google Scholar]
8. Coupar E. B. H., Andrew M. E., Both G. W., Boyle V. 1986; Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. European Journal of Immunology 16:1479–1487
   [Google Scholar]
9. Cranage M. P., Kouzarides T., Bankier A., Satchwell S., Weston K., Tomlinson P., Barrell B. 1986; Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EM BO Journal 5:3057–3063
   [Google Scholar]
10. Del Val M., Schlicht H. -J., Volkmer H., Messerle M., Reddehase M. J., Koszinowski U. 1991; Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. Journal of Virology 65:3641–3646
    [Google Scholar]
11. Gibson M., Tiensiwakul P., Khoobyarian V. 1982; Adenovirus fiber protein (FP) functions as a mitogen and an adjuvant. Cellular Immunology 73:397–103
    [Google Scholar]
12. Glenn J. 1981; Cytomegalovirus infections following renal transplantation. Reviews of Infectious Diseases 3:1151–1178
    [Google Scholar]
13. Gönczöl E., Furlini G., Ianacone J., Plotkin S. A. 1986a; A rapid microneutralization assay for cytomegalovirus. Journal of Virological Methods 14:37–41
    [Google Scholar]
14. Gönczöl E., Hudecz F., Ianacone J., Dietzschold B., Starr S., Plotkin S. A. 1986b; Immune responses to isolated human cytomegalovirus envelope proteins. Journal of Virology 58:661–664
    [Google Scholar]
15. Gönczöl E., Ianacone J., Ho W., Starr S., Meignier B., Plotkin S. A. 1990; Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8:130–136
    [Google Scholar]
16. Gönczöl E., DeTaisne C., Hirka G., Berencsi K., Lin W., Paoletti E., Plotkin S. A. 1991; High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine 9:631–637
    [Google Scholar]
17. Hosmalin A., Clerici M., Houghten R., Pendleton C. D., Flexner C., Lucey D. R., Moss B., Germain R. N., Shearer G. M., Berzofsky J. A. 1990; An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proceedings of the National Academy of Sciences, U.S.A 87:2344–2348
    [Google Scholar]
18. Liu Y. -N. C., Klaus A., Kari B., Stinski M. F., Eckhardt J., Gehrz R. C. 1991; The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulate both B- and T-cell immune responses in humans. Journal of Virology 65:1644–1648
    [Google Scholar]
19. Marshall G. S., Ricciardi R. P., Rando R., Puck J., Ge R., Plotkin S. A., Gönczöl E. 1990; An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. Journal of Infectious Diseases 162:1177–1181
    [Google Scholar]
20. Masuho Y., Matsumoto Y.I., Sugano T., Fujinaga S., Minamishima Y. 1987; Human monoclonal antibodies neutralizing human cytomegalovirus. Journal of General Virology 68:1457–1461
    [Google Scholar]
21. Rawle F. C., Tollefson A. E., Wold W. S. M., Gooding L. R. 1989; Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gpl9K but not E317.7K. Journal of Immunology 143:2031–2037
    [Google Scholar]
22. Riddell S. R., Rabin M., Geballe A. P., Britt W. J., Greenberg P. D. 1991; Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. Journal of Immunology 146:2797–2803
    [Google Scholar]
23. Tanaka Y., Isobe A., Masuda M., Tozawa H., Koyanagy Y., Yamamoto N., Shida H. 1991; Immunogenicity of human T cell leukemia virus type-I (HTLV-I) antigens for cytotoxic T lymphocytes in the rat system. Journal of Immunology 147:3646–3652
    [Google Scholar]
24. Tartaglia J., Pincus S., Paoletti E. 1990; Poxvirus-based vectors as vaccine candidates. Critical Reviews in Immunology 10:13–30
    [Google Scholar]
25. Townsend A., Bastin J., Gould K., Brownlee G., Andrew M., Coupar B., Boyle D., Chan S., Smith G. 1988; Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. Journal of Experimental Medicine 168:1211–1224
    [Google Scholar]
26. Weller T. H. 1971; The cytomegalovirus: ubiquitous agents with protean clinical manifestations. New England Journal of Medicine 285:203–214
    [Google Scholar]
27. Zhou J., McIndoe A., Davies H., Sun X. -Y., Crawford L. 1991; The induction of cytotoxic T-lymphocyte precursor cells by recombinant vaccinia virus expressing human papillomavirus type 16 L1. Virology 181:203–210
    [Google Scholar]